J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

But the increased risk applies across all age groups, and the company’s Sanofi-Pasteur vaccines unit has proposed a label update asking doctors to assess the likelihood of previous infection ...

Similar to Sanofi Pasteur, they also label pre-filled syringes and employ vial caps with a unique color to differentiate each of its vaccines and have a statement on the packaging for Boostrix ...

The newly merged company also formed a subsidiary known as Sanofi Pasteur, which is today one ... there are 65 new molecular entity projects and vaccine candidates already in clinical development.

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Panacea Biotec shares touched a new 52-week high on Tuesday after Sanofi Healthcare India agreed to not commercially produce its fully liquid hexavalent vaccine Shan6 in India, directly or ...

Panacea Biotec has resolved a patent infringement lawsuit with Sanofi Healthcare concerning its EasySix hexavalent vaccine. Under the settlement, Sanofi will refrain from launching its Shan6 ...

In all, the partners plan to provide enough supply to cover every eligible infant in the U.S. Sanofi has begun shipping the ...